Denis Harrington, who until recently was head of sales for Boston Scientific Corp.’s cardiovascular and CRM business, has left the company to become president and CEO of a Twin Cities startup called BridgePoint Medical Inc.
Harrington has replaced BridgePoint co-founder Chad Kugler as the five-year-old company’s top executive, according to a company news release. Kugler is staying with the company as chief operating officer.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Harrington has been at Boston Scientific (NYSE: BSX) and SciMed for the past 18 years, and has more than 22 years experience in the medical technology business.
Plymouth, Minnesota-based BridgePoint is developing technologies meant to treat severe blockages in patients’ arteries. It recently completed a $9.1 million round of financing, led by a new strategic investor and joined by existing investors New Enterprise Associates, Polaris Venture Partners, Foundation Medical Partners and Michael Berman.
